Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Immune Response Suppliers Serving Europe
212 companies found
based inUppsala, SWEDEN
Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. Our groundbreaking Olink panels for precision proteomics help ...
Casting a broader net to further explore the complexity of the human proteome. Complementing and expanding on our previous portfolio of disease area-focused biomarker panels, our exploratory panels offers scientists the chance to cast a wider net in ...
based inGaithersburg, MARYLAND (USA)
As a global life sciences company, Emergent offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. Protecting and Enhancing 50 million lives by 2025 focuses our energy to improve the ...
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
based inVancouver, BRITISH COLUMBIA (CANADA)
At AbCellera, team is everything. When great people share a vision and work together, they can truly have a positive impact on the world. That™s why we hire for character and intelligence, not for CVs or experience. We look for people with drive and ...
We search, decode, and analyze natural immune systems to find antibodies that our partners can develop into drugs that improve ...
based inSarıyer, TURKEY
Virasoft Inc. was founded in 2015 with the support of the Turkish Ministry of Industry and Technology. We develop institution-specific projects in 4 main areas that meet all the needs of an institution in digital pathology. We focus on four main ...
But PD-L1 can be expressed by tumor cells and tumor stroma. Interaction tumoral PD-L1 with PD-1 stimulates PD-1-mediated T cell inhibition and down regulation of immune response. PD-L1-PD-1 pathway has proven value ...
based inMölndal, SWEDEN
Alzinova AB is a Swedish clinical-stage biopharma company pioneering the development of an active immunotherapy against Alzheimer’s disease. The vaccine is in clinical development and tested in patients. The company’s shares (ALZ) are listed on ...
ALZ-101 is a vaccine that stimulates the production of antibodies against the toxic Aβ oligomers. A first-in-human study in patients with early Alzheimer’s disease was initiated during third quarter of ...
based inBække, DENMARK
European Protein AS was founded in 2011 by Lone and Jens Legarth with the aim to develop and produce a dried, lactic acid fermented protein feed primarily to pigs but also to other livestock such as poultry, fish, etc. Based on personal experience ...
EP199 is a non-GMO complementary and functional rapeseed and seaweed protein supporting gut health, immune system development and contains antibacterial and anti-inflammatory compounds effective across ...
based inGuangzhou, CHINA
Guangzhou Wondfo Biotech Co., Ltd., headquartered in Guangzhou science city, has been focusing on the R&D, production, sales and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic ...
RBD (receptor binding domain) of 2019-nCoV virus S1 protein is the region that binds to the ACE2 receptor on human cells as the first step of virus invading. The majority and most potency neutralizing antibody targets the epitopes on RBD, therefore ...
based inLondon, UNITED KINGDOM
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic ...
At TREOS we use knowledgebase and algorithm embedded in PASCal (Personal Antigen Selection Calculator) tool to develop personal cancer immunotherapies. PASCal supports the development of immunotherapies for single individuals and a population of ...
based inFramingham, MASSACHUSETTS (USA)
Kephera Diagnostics is a startup that aims to address the public health challenges of global infectious diseases with point of care assay technology. We collaborate with a global community of researchers to develop and translate new technologies ...
COVI-QUANT™ is an ELISA test available through Kephera’s CLIA laboratory. Studies show that not all individuals develop a strong immune response after COVID-19 infection or vaccination, especially those ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Due to poor immunogenic properties and low molecular weight, your antigen is going to be eliminated in animal urine without generating any humoral immune response. That's why we've created SynAbs in the first place, ...
based inBreitenfurt, AUSTRIA
Privately held OncoQR ML, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodulation) technology ...
Cancer cells have the ability to escape our immune system´s defenses – by outsmarting checkpoint molecules on our immune cells. For more than three decades, science and industry have been working to overcome cancer’s tricky battle ...
based inLondon, UNITED KINGDOM
Juno Bio is for women and people with vaginas who want to learn more about their microbes. Juno Bio tests are currently exclusively intended to be used for wellness purposes. The tests we offer are not intended to diagnose or treat disease, or to ...
Human Papillomavirus (HPV) is a class of viruses that can infect both men and women and is often sexually transmitted. While many cases are harmless and will resolve on their own, some strains of HPV can lead to serious complications for women ...
based inDijon, FRANCE
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, ...
Oncodesign’s Pharmimage® technology module is a pharmaco-imaging module designed to monitor the effect of treatments and to define effective translational biomarkers in precision medicine. It includes translational, optical ...
based inSchlieren, SWITZERLAND
Virometix is a clinical stage biotech company pioneering a new class of synthetic vaccines to tackle infectious diseases and cancer. Our structure-based vaccines are designed to direct a precise, robust and sustained immune response. With a ...
Our vaccine candidate – already in clinical phase I – demonstrates strong, durable, specific and protective immune responses, with minimal risk of vaccine-associated enhanced respiratory disease ...
based inTel-Aviv, ISRAEL
RedHill Biopharma (NASDAQ: RDHL) is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on our promises, to build a company at the forefront of ...
Opaganib (ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
We believe our IntelliSelect® Technology platforms reduce the risk of missing novel solutions and increase the quality and differentiation of antibodies, to identify product candidates with the most desirable drug-like ...
based inLancaster, CALIFORNIA (USA)
Simulations Plus provides cutting-edge software solutions and consulting services designed to enhance drug discovery, clinical development, and regulatory submission processes. With over 25 years of experience, the company has established itself as ...
DILIsym integrates compound exposure with mechanisms of drug toxicity and inter-individual variability, offering insights into hepatotoxicity prediction for multiple species, including mice, rats, dogs, and humans. Its comprehensive sub-models cover ...
based inNewark, DELAWARE (USA)
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across ...
Interleukin-21 (IL-21) is a secreted protein which belongs to the IL-15 / IL-21 family. Interleukin-21 / IL-21 belongs to a family of cytokines that bind to a composite receptor consisting of a private receptor (IL21R) and the common cytokine ...
based inSouth Melbourne, AUSTRALIA
BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. Our business model is to generate income from partnerships including with other vaccine and infectious ...
A core technology advantage: Live Attenuated Influenza Virus (LAIV) vaccine. BioDiem’s lead asset is the Live Attenuated Influenza Virus (LAIV) vaccine technology. Our LAIV vaccine licensing business involves out-licensing of the ...